DERM Stock Analysis: Buy, Sell, or Hold?
DERM - Journey Medical Corporation Common Stock
$6.11
-0.23 (-3.63%)
▼
5d:
-1.13%
30d:
-3.48%
90d:
-18.53%
BUY
MODERATE Confidence
Analysis Updated: Jun 16, 2026 12:00 AM ET
Earnings: May 19, 2026
0d
Get Alerted When DERM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DERM shows positive signals but monitor for confirmation. Market pricing in 34.0% decline. Moderate conviction.
💡 BUY OPPORTUNITY: DERM shows positive signals but monitor for confirmation. Market pricing in 34.0% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$41.42
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$25.72
76.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DERM is currently trading at $6.11, which is considered fair relative to its 30-day fair value range of $5.66 to $6.41. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.9) compared to its historical average (20.5). Remarkably, the market is currently pricing in an annual earnings decline of 34.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, DERM is in a strong downtrend. Immediate support is located at $5.80, while resistance sits at $6.46. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.50 (+120.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DERM is in a strong downtrend. Immediate support is located at $5.80, while resistance sits at $6.46. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.50 (+120.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.66 -
$6.41
Company Quality Score
59/100
(HOLD)
Options IV Signal
44th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
68.1%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 44th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 120.9% below Wall St target ($13.50)
Trading Range Analysis
30-Day Trading Range
$5.66 -
$6.41
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.75
(12.2%)
Support & Resistance Levels
Support Level
$5.80
Resistance Level
$6.46
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.89
Wall Street Target
$13.50
(+120.9%)
Revenue Growth (YoY)
21.5%
Profit Margin
-14.8%
Valuation Discount vs History
-34.0% cheaper
PE vs Historical
5.9 vs 20.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-34.0%
(market-implied from PE analysis)
1-Year Target
$5.50
(-10%)
2-Year Target
$4.95
(-19%)
3-Year Target
$4.45
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6→21)
$15.50
(+154%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 1496.2%)
$76.26
(+1148%)
Base:
(SPY PE: 5.9, Growth: 1496.2%)
$20.62
(+238%)
Bear:
(PE: 5.0, Growth: 1496.2%)
$17.53
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.9 to 20.5
Stabilization Target:
$21.27
(+248.1%)
PE Expansion Potential:
+248.1%
Share & Embed Analysis
Last updated: June 17, 2026 1:45 AM ET
Data refreshes hourly during market hours. Next update: 2:45 AM
Data refreshes hourly during market hours. Next update: 2:45 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DERM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$193 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 57 HOLD |
